Significant evidence has suggested that nuclear factor erythroid-related factor 2 (NRF2) acts as a key regulator of antioxidant responses, which favors cancer cell growth and leads to increased drug resistance in tumor cells [87,88,89]. This evidence concerns the gene NFE2L2 and cancer.